Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivi...
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in comb...
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Interaction Between Cocaine and Quetiapine - 1
- Conditions
- First Posted Date
- 2004-07-16
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 12
- Registration Number
- NCT00087750
- Locations
- 🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States
Treatment and Outcome of Early Onset Bipolar Disorder
- Conditions
- First Posted Date
- 2002-11-13
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 40
- Registration Number
- NCT00048802
- Locations
- 🇺🇸
The Zucker Hillside Hospital, Long Island Jewish Medical Center, Glen Oaks, New York, United States
Switching Medication to Treat Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2002-09-05
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 219
- Registration Number
- NCT00044655
Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)
- Conditions
- First Posted Date
- 2002-08-15
- Last Posted Date
- 2009-12-11
- Lead Sponsor
- National Institute on Aging (NIA)
- Target Recruit Count
- 60
- Registration Number
- NCT00043849
- Locations
- 🇺🇸
Fletcher Allan Health Care, Inc., Burlington, Vermont, United States
🇺🇸Memory Clinic at Southwestern Vermont Medical Center, Bennington, Vermont, United States
🇺🇸University of Pittsburgh, Alzheimer's Disease Research Center, Pittsburgh, Pennsylvania, United States
Antipsychotic Response in Schizophrenia
- Conditions
- First Posted Date
- 2001-07-05
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00018668
- Locations
- 🇺🇸
Department of Veterans Affairs, San Diego, California, United States
Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder
- Conditions
- First Posted Date
- 2001-07-05
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00018642
- Locations
- 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
CATIE-Alzheimer's Disease Trial
- Conditions
- First Posted Date
- 2001-04-23
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 450
- Registration Number
- NCT00015548
- Locations
- 🇺🇸
VA Medical Center, Coatesville, Pennsylvania, United States
🇺🇸University of California, Irvine Medical Center, Irvine, California, United States
🇺🇸Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States
CATIE- Schizophrenia Trial
- Conditions
- First Posted Date
- 2001-04-09
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 1600
- Registration Number
- NCT00014001
- Locations
- 🇺🇸
Staten Island University Hospital, Staten Island, New York, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Northwestern Medical School Department of Psychiatry, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.